Comera Life Sciences Holdings, Inc. (CMRA)
Market Cap | 30.50M |
Revenue (ttm) | n/a |
Net Income (ttm) | n/a |
Shares Out | 22.27M |
EPS (ttm) | -6.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 238,710 |
Open | 1.42 |
Previous Close | 1.41 |
Day's Range | 1.31 - 1.52 |
52-Week Range | 1.11 - 15.30 |
Beta | 0.98 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 9, 2023 |
About CMRA
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Scien... [Read more]
Financial Performance
Financial StatementsNews

Comera Life Sciences to Present at 22nd Annual PepTalk Conference
WOBURN, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biolo...

Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...

Comera Life Sciences to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference
WOBURN, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...

Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company –

Comera Life Sciences Announces Favorable Preclinical Results of Lead SQore Excipient in SEQURUS-2 Study
WOBURN, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...

Comera Life Sciences Expands Woburn Operations
Elected Officials, Industry Leaders Celebrate Biotech Workforce Growth at Ribbon-Cutting Event

Insiders Are Buying Up Comera Life Sciences (CMRA) Stock. Here's Why.
Shares of Comera Life Sciences (NASDAQ: CMRA) are up by over 30% following a flurry of insider purchases. As the name suggests, Comera is a life sciences company that seeks to improve traditional int...

Comera Life Sciences Announces Up To $15 million Purchase Agreement with Arena Business Solutions
WOBURN, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biolo...

Comera Life Sciences Provides Business Highlights and Reports Financial Results for the Second Quarter 2022
WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve...

Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, ...

Comera Life Sciences Appoints Michael Campbell as Executive Vice President and Chief Financial Officer
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, ...

What's Going On With OTR Acquisition Stock Today?
OTR Acquisition Corp (NASDAQ: OTRA) shares are trading higher Wednesday after the company filed a Form 8-K with the U.S. Securities and Exchange Commision. The move appears to be related to the high n...

Why Is OTR Acquisition (OTRA) Stock Up Today?
The shares of OTR Acquisition are climbing after the SPAC's shareholders overwhelmingly approved a merger with Comera. The post Why Is OTR Acquisition (OTRA) Stock Up Today?

Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and...

Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announce...

Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration
WOBURN, Mass. & AHMEDABAD, India--(BUSINESS WIRE)--Today, Comera Life Sciences, Inc. (“Comera” or the “Company”) and Intas Pharmaceuticals Ltd. (“Intas”) announced a research collaboration to develop ...

Comera Life Sciences and OTR Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination
WOBURN, Mass. & MIAMI--(BUSINESS WIRE)--Comera Life Sciences, Inc. (“Comera”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenie...